The tumor suppressor gene TP53 is frequently mutated in breast cancer (BC) and is associated with poor prognosis. Identifying additional features that may assist in diagnosis, treatment, and prognostic stratification remains essential. This study aimed to evaluate the presence of TP53 mutations and their association with histological and molecular subtypes of BC. A total of 990 breast cancer samples from The Cancer Genome Atlas (TCGA) were analyzed using somatic variant data. The maftools package in RStudio was used to perform group comparisons via Fisher's exact test and odds ratio (OR) calculations. P-values were adjusted using the Benjamini-Hochberg method, with padj < 0.05 considered statistically significant. TP53 mutations were associated with distinct molecular and histological subtypes of breast cancer. These variants were significant in the Luminal A subtype (padj = 8.76e-31, OR = 0.095), although correlated with lower risk, consistent with this subtype’s favorable prognosis. In contrast, TP53 mutations were strongly associated with the Basal- like subtype (padj = 3.45e-26, OR = 23.68), known for its aggressiveness and resistance to conventional therapies. This resistance may be driven by TP53-mediated molecular alterations that promote cell survival under therapeutic pressure. Histologically, TP53 mutations were less frequent in invasive lobular carcinoma (padj = 4.15e-38, OR = 0.035) and more common in invasive ductal carcinoma (padj = 1.36e-25, OR = 9.13), suggesting its potential as a discriminative molecular marker. Additionally, significant co-occurrence was observed between TP53 mutations and alterations in CDH1 (padj = 1.27e-48, OR = 0.023) and PTEN (padj = 1.07e-05, OR = 0.226), reinforcing its integration within complex molecular networks. These findings highlight the central role of TP53 in shaping the biological behavior of breast cancer. Its mutations are linked to greater aggressiveness, genomic instability, and disease progression, whereas their lower frequency in favorable subtypes may suggest a protective role when functional. The observed associations with CDH1 and PTEN mutations further underscore TP53’s relevance as a prognostic biomarker and its potential utility in risk stratification and in understanding breast cancer heterogeneity
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
